Vin Menon, Co-Chief Executive Officer of Apimeds Pharmaceuticals US, Inc., filed an initial statement of beneficial ownership on November 2, 2026, reporting a derivative securities position tied to a date-of-event of December 1, 2025.

Key Highlights

  • Reporting person: Vin Menon, identified as Co-Chief Executive Officer of Apimeds Pharmaceuticals US, Inc. (NYSE American:APUS).
  • Event date: The date of event requiring the statement is listed as December 1, 2025.
  • Derivative security held: Series A Convertible Preferred Stock, owned directly, with no expiration date according to the filing.
  • Underlying shares: The Series A Convertible Preferred Stock is convertible into 484,775 shares of Common Stock as of the event date, as adjusted for the issuer's 1-for-10 reverse stock split effective July 23, 2026.
  • Conversion terms: Each share of Series A Convertible Preferred Stock converts into 20 shares of Common Stock, subject to adjustment under the Certificate of Designation, with no additional consideration payable upon conversion.
  • Non-derivative holdings: No non-derivative securities are reported in Table I of the filing.

Menon's Initial Ownership Filing: Series A Preferred Stock and Conversion Conditions

According to the filing, Vin Menon submitted this initial statement of beneficial ownership in his capacity as Co-Chief Executive Officer of Apimeds Pharmaceuticals US, Inc., traded on NYSE American under the symbol APUS. The filing covers a date of event of December 1, 2025, and was signed and submitted on November 2, 2026. Menon filed as an individual reporting person and did not report any direct holdings of common stock in Table I.

The sole position reported is in Table II, covering derivative securities. The filing discloses that Menon directly holds Series A Convertible Preferred Stock that is convertible into 484,775 shares of Common Stock as of the event date. The filing notes this figure is "as adjusted for the Issuer's 1-for-10 reverse stock split effective July 23, 2026." The conversion ratio is stated as 20 shares of Common Stock per share of Series A Convertible Preferred Stock, subject to adjustment under the Certificate of Designation, and the filing specifies that "no additional consideration is payable upon conversion."

The filing further explains that the Series A Convertible Preferred Stock is not convertible at the option of the holder. According to the disclosure, each share "will automatically convert into shares of Common Stock on the third business day following the later of (i) the effectiveness of stockholder approval of the conversion under NYSE American rules and (ii) NYSE American's approval of the Issuer's new listing application." No expiration date applies to the Series A Convertible Preferred Stock, as noted in the filing's explanation of responses.

What Was Disclosed

Vin Menon, Co-Chief Executive Officer of Apimeds Pharmaceuticals US, Inc. (NYSE American:APUS), filed an initial beneficial ownership statement reporting Series A Convertible Preferred Stock convertible into 484,775 shares of Common Stock, with automatic conversion contingent on stockholder and NYSE American approval.